Team : Laura Caviezel, Siméone de Fremond, Danayit Gebreyohannes, Sydney Gray, Aditya Ramamurthy

Diasome Executive Summary: Revolutionizing Type 2 Diabetes Management with a Groundbreaking Therapy

Situation

A biotechnology company is poised to enter the Type 2 Diabetes market with a novel oral therapy currently under pre-clinical development. This therapy leverages advanced nanotechnology to achieve a new mechanism of action addressing the underlying physiology of Type 2 Diabetes. With a projected launch within the next 5-7 years, this innovative solution aims to address critical unmet needs in diabetes treatment. The therapy’s success depends on achieving a compelling market position supported by a strategic approach to differentiation, pricing power, and integration within the evolving treatment ecosystem.

Problem: Competing in a Complex and Crowded Market

The Type 2 diabetes market is characterized by a highly stratified treatment landscape, ranging from early-stage interventions to advanced-stage therapies. To secure investor confidence and commercial partnerships, the company must position its therapy effectively to deliver meaningful health outcomes, meet physician and patient needs, and justify pricing. This requires a careful alignment of clinical feasibility, physician acceptance, and commercial viability to ensure its success against existing treatment options and emerging competitions.

Strategic Approach: Evaluating Positioning Options for Optimal Impact

We conducted an analysis of the treatment landscape to identify the best market entry strategy. We explored four positioning options –

1) Standalone Pill (Pre-diagnosis): A preventative therapy aimed at halting disease progression before diagnosis of Type-2 Diabetes specific to individuals with a risk of Type-2 Diabetes.

2) Adjuvant Combination Pill (Early/Mid Stage): A co-formulated therapy with a GLP-1 drug to enhance clinical outcomes while reducing pill burden.

3) Add-On Separate Pill (Early/Mid Stage): A catalyst therapy to stabilize disease progression and delay the need for injectable treatments.

4) Escalation Separate Pill (Late Stage): A targeted lower-dose therapy aimed at reducing advanced complications.

By pressure-testing conditions for success—patient need, physician acceptance, clinical endpoints and commercial potential—supported by detailed physician and provider interviews, we identified the adjuvant combination pill as the optimal solution. This approach effectively addresses the largest patient segment, simplifies treatment regimens, enhances the clinical durability of the standard-of-care API, and provides a compelling value proposition for all stakeholders. This positioning ensures alignment with market needs while delivering sustainable impact across the Type-2 Diabetes treatment continuum.

Recommendation: Introducing a game-changing adjuvant therapy

We recommend positioning the therapy as an adjuvant combination pill, co-formulated with GLP-1, for an early patient population. This approach capitalizes on improving glucose control, reducing cardiovascular risk, minimizing pill burden, and addressing a critical gap in the current treatment landscape. Unlike standalone therapies, this combination pill enhances outcomes through a unique mechanism targeting multiple pathways, offering a differentiated and highly competitive product.

Impact: A Market Shaper with Transformational Potential

By adopting this positioning, the company can redefine diabetes management and capture a significant share of the early/mid-stage patient population. The therapy has demonstrated potential to become the first disease-modifying agent in its class, delivering substantial commercial value and addressing the high economic burden of diabetes through a multi-indication strategy. Partnering with an established player to co-develop this therapy extends the lifecycle of current blockbuster GLP-1 drugs, while offering promise for a broad range of indications with meaningful competitive advantage.

This strategy positions the company as a market innovator, improving patient outcomes while creating a compelling narrative for investors, partners, and healthcare providers.